Torrent Pharmaceuticals Share Price

Torrent Pharma.

CMP as on 20-May-22 15:29

₹ 2,675.00
82.70 3.19%

Open

₹ 2,612.50

Turnover (lac)

₹ 11,641

Prev. Close

₹ 2,592.30

Day's Vol (shares)

₹ 4,35,196

Day's Range (₹)

₹ 2,591.00
₹ 2,679.90

CMP as on20-May-22 15:29

₹ 2,678.65
87.3 3.37%

Open

₹ 2,611.45

Turnover (lac)

₹ 146

Prev. Close

₹ 2,591.35

Day's Vol (shares)

₹ 2,730

Day's Range

₹ 2,592.20
₹ 2,681.80

CMP as on 20-May-22 0:00

₹ 2,680.75
86.05 3.32%

Open

₹ 2,619.40

Open Interest(Contracts)

₹ 6,43,250

VWAP

₹ 2,646.47

Day's Vol (shares)

₹ 2,97,000

Day's Range (Ex.Dt. 26 May 2022)

₹ 2,593.45
₹ 2,685.40

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 11-May-2022 - -
Appointment of Dr. Maurice Chagnaud as an Additional and Independent Director of the Company
Board Meeting - 10-Jan-2022 - -
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/01/2022 inter alia to consider and approve We would like to inform you that the meeting of the Board of Directors will be held on Tuesday 25-Jan-22 inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and nine months ended on 31-Dec-21. The Board would also consider payment of Interim Dividend for the year 2021-22. We would like to inform that the Board has at its meeting held today approved an interim dividend of Rs. 25/- (500 %) per equity share of Rs. 5/- fully paid up. The dividend is expected to be paid / dispatched on or around 11th February, 2022. We would like to inform that the Board has at its meeting held today approved, inter-alia, the following: 1) Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with the limited review report of the Company for the quarter and nine months ended on 31st December, 2021. The said financial results are enclosed herewith. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of Unaudited Consolidated Financial Results for the quarter and nine months ended on 31st December, 2021. Both Standalone and Consolidated Financial Results will be available at Companys website www.torrentpharma.com. A Press Release on Financial Results which is being submitted to the media is also enclosed herewith. (As Per BSE Announcement Dated on 25.01.2022)
Board Meeting - 11-Oct-2021 - -
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2021 ,inter alia, to consider and approve We would like to inform you that a meeting of the Board of Directors will be held on Tuesday, 26-Oct-21, inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on 30-Sep-21. Outcome of Board Meeting dated 26-Oct-2021 (As per BSE Announcement Dated on 26/10/2021)
Board Meeting - 09-Jul-2021 - -
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2021 ,inter alia, to consider and approve We would like to inform you that a meeting of the Board of Directors will be held on Tuesday, 27-Jul-21, inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter ended on 30-Jun-21. Outcome of Board Meeting dated 27-Jul-2021 (As per BSE Announcement Dated on 27/7/2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity